Dennis E. J. G. J. Dolmans

TL;DR: PDT is being tested in the clinic for use in oncology — to treat cancers of the head and neck, brain, lung, pancreas, intraperitoneal cavity, breast, prostate and skin.

TL;DR: Mechanistic insights into antitumor vascular effects of PDT are provided and novel strategies for tumor treatment with PDT are suggested and suggested.

TL;DR: The increased pO2 during anti-VEGFR-2 mAb and hormone ablation therapy may explain the observed beneficial effects of combining antiangiogenic or hormone therapies with radiation treatment, and is critical for optimal scheduling of these treatment modalities.

TL;DR: In vivo growth and vascular function in tumors derived from two VEGF-C-overexpressing and mock-transfected cell lines are quantified and suggest that VEGFR-2 signaling is critical for tumor angiogenesis and vascular permeability and that V EGFR-3 signaling does not compensate for VEG FR-2 blockade.

TL;DR: The effects of PDT on an orthotopic, murine mammary tumor model is reported for the first time and the fractionated drug dose PDT more effectively induced tumor growth delay than the same total dose given as a single dose either at 4 h or at 15 min before light administration.